Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma

Fatigue is the Most Important Symptom for Advanced Cancer Patients Who Have Had Chemotherapy

(2017) Zeeshan Butt et al.   Journal of the National Comprehensive Cancer Network

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

(2012) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies

(2012) T. Eisen et al.   JNCI-Journal of the National Cancer Institute

Impact of response shift on longitudinal quality-of-life assessment in cancer clinical trials

(2011) Zeinab Hamidou et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis

(2010) D Cella et al.   BRITISH JOURNAL OF CANCER

Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice

(2010) Manuela Schmidinger et al.   CANCER INVESTIGATION

Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies

(2010) J. M. G. Larkin et al.   ONCOLOGIST

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

(2009) Martin E Gore et al.   LANCET ONCOLOGY

Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial

(2008) David Cella et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies

(2008) T. E. Hutson et al.   ONCOLOGIST